Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events in Adults with T2D

 Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events in Adults with T2D

Janssen’s (J&J) Invokana (canagliflozin) Receives FDA Approval for MACE events in Adults with T2D

Shots:

  • The approval is based on the results of CANVAS (CANagliflozin cardioVascular Assessment Study) Program assessing Invokana vs PBO + SoC in 10,000 adults having or at risk CV disease with T2D & recommendations from ADA & AACE for Invokana + SGLT2 inhibitor to reduce CV events
  • CANVAS study results: overall reduction in risk of heart attack, stroke and CV death 14%; with CV disease 18%; Reduction in MACE events 18%; MACE risk reduction nonfatal heart attack, nonfatal stroke, CV death (15%, 10%, 13%)
  • Invokana PO is a novel medication approved for reduction in MACE events. Janssen has acquired US rights of Invokana from Mitsubishi Tanabe and also received first FDA approval on 29 Mar, 2018 indicated for glycemic control in adults with T2D

Click here to read full press release/ article | Ref: J&J| Image: Pharmafile

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post